Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (211-220 of 284) with videos related to

Pageof 29
Sort By:
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Clinical Colorectal Cancer|June 10, 2020
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of MilanFilippo Pietrantonio, Federica Morano, Monica Niger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2019
Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyFederica Morano, Salvatore Corallo, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trialsRoberto Moretto, Salvatore Corallo, Antonino Belfiore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal CancerJim P Abraham, Daniel Magee, Chiara Cremolini, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patientsUmberto Malapelle, Francesco Passiglia, Chiara Cremolini, et al.
JAMA Oncology|February 17, 2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical TrialChiara Cremolini, Carlotta Antoniotti, Sara Lonardi, et al.
Pageof 29

Showing results (211-220 of 284) with videos related to

Sort By:
Pageof 29
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Clinical Colorectal Cancer|June 10, 2020
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of MilanFilippo Pietrantonio, Federica Morano, Monica Niger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2019
Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyFederica Morano, Salvatore Corallo, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trialsRoberto Moretto, Salvatore Corallo, Antonino Belfiore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal CancerJim P Abraham, Daniel Magee, Chiara Cremolini, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patientsUmberto Malapelle, Francesco Passiglia, Chiara Cremolini, et al.
JAMA Oncology|February 17, 2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical TrialChiara Cremolini, Carlotta Antoniotti, Sara Lonardi, et al.
Pageof 29